# Kim Papp

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kim-papp/

## Facts

| Field | Value |
| --- | --- |
| Citations | 49,985 |
| Field | Psoriasis: Treatment and Pathogenesis |
| h-index | 108 |
| i10-index | 370 |
| Last Known Institution | University of Toronto |
| OpenAlex ID | https://openalex.org/A5008286260 |
| ORCID iD | https://orcid.org/0000-0001-9557-3642 |
| Works | 816 |

## Researcher papers

Showing 12 of 18.

- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody-2/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial](https://scholariq.org/papers/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody/)
- [Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa](https://scholariq.org/papers/two-phase-3-trials-of-adalimumab-for-hidradenitis-suppurativa/)
- [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials](https://scholariq.org/papers/once-daily-upadacitinib-versus-placebo-in-adolescents-and-adults-with-moderate/)
- [Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials](https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/)

## Researcher topics

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Pharmaceutical studies and practices](https://scholariq.org/topics/pharmaceutical-studies-and-practices/)

## Researcher university

- [University of Toronto](https://scholariq.org/institutions/university-of-toronto/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.